If you have been reading about AOD-9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
== Significance of work == But for Eugene Garfield's 1986 tribute to De in Current Contents, De's great contributions to cholera research would have remained unknown to many even in India. A special issue of the journal Current Science was published in 1990 in his honour, to which several eminent scientists of national and international repute contributed. In the words of Dr S Sriramachari, former director of the Institute of Pathology and additional director general of the Indian Council of Medical Research, New Delhi, De's contributions stand out as a pinnacle of excellence in our understanding of the pathogenesis of cholera. Nobel laureate Prof. Joshua Lederberg had nominated De for the Nobel Prize more than once. Said Lederberg, "our appreciation of De must then extend beyond the humanitarian consequences of his discovery. . . he is also an examplar and inspiration for a boldness of challenge to the established wisdom, a style of thought that should be more aggressively taught by example as well as precept.” De was never elected a fellow of any Indian academy and never received any major award. Indeed as Professor Padmanabhan Balaram pointed out in an editorial in Current Science, "De died in 1985 unhonoured and unsung in India's scientific circles. That De received no major award in India during his lifetime and our Academies did not see it fit to elect him to their Fellowships must rank as one of the most glaring omissions of our time.
Therefore, an effective cure will require a sequential, integrated approach that combines adequate and safe immune interventions with beta cell regenerative approaches. It has also been demonstrated that alpha cells can spontaneously switch fate and transdifferentiate into beta cells in both healthy and diabetic human and mouse pancreatic islets, a possible future source for beta cell regeneration. In fact, it has been found that islet morphology and endocrine differentiation are directly related. Endocrine progenitor cells differentiate by migrating in cohesion and forming bud-like islet precursors, or "peninsulas", in which alpha cells constitute the peninsular outer layer and beta cells form later beneath them. Cryopreservation has shown promise to improve the supply chain of pancreatic islets for better transplantation outcomes.
The earliest known description of the disease was in 1841 by the American physician Charles Oscar Waters. The condition was described in further detail in 1872 by the American physician George Huntington. The genetic basis was discovered in 1993 by an international collaborative effort led by the Hereditary Disease Foundation. Research and support organizations began forming in the late 1960s to increase public awareness, provide support for the afflicted and their families, and promote research. Research directions include determining the exact mechanism of the disease, improving animal models to aid with research, testing of medications and their delivery to treat symptoms or slow the progression of the disease, and studying procedures such as stem-cell therapy with the goal of replacing damaged or lost neurons.
Sources: en.wikipedia.org
== Early life and education == She was born on June 26, 1946, in Manhattan, New York City. She completed her undergraduate studies in biology, cum laude in 1970 from Bryn Mawr College in Pennsylvania.
== Toxicity == Several typical mechanisms underlying graphene (oxide) nanomaterial's toxicity have been revealed, for instance, physical destruction, oxidative stress, DNA damage, inflammatory response, apoptosis, autophagy, and necrosis. In these mechanisms, toll-like receptors (TLR), transforming growth factor-beta (TGF-β) and tumor necrosis factor-alpha (TNF-α) dependent-pathways are involved in the signalling pathway network, and oxidative stress plays a crucial role in these pathways. Many experiments have shown that graphene (oxide) nanomaterials have toxic side effects in many biological applications, but more in-depth study of toxicity mechanisms is needed. According to the USA FDA, graphene, graphene oxide, and reduced graphene oxide elicit toxic effects both in vitro and in vivo. Graphene-family nanomaterials (GFN) are not approved by the USA FDA for human consumption.
Welsh Conservatives leader Darren Millar unveils his Shadow Cabinet. 13 December – The UK unveils plans to achieve 95% clean energy by 2030, including giving powers to ministers to have the final say in the approval of onshore windfarms. 15 December – Foreign Secretary David Lammy confirms the UK government has had "diplomatic contact" with Hayat Tahrir al-Sham, the Syrian rebel group that overthrew the Assad regime. The UK joins the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP), a trade agreement involving several Asian and Pacific countries, including Japan and Australia. 16 December – Deputy Prime Minister Angela Rayner outlines proposals to redesign local government, with plans for every region in England to have a directly-elected mayor. 17 December – British diplomats have held talks with Hayat Tahrir al-Sham leader Ahmed al-Sharaa (formerly known as Abu Mohammad al-Julani) in Damascus. Education Secretary Bridget Phillipson introduces the Children's Wellbeing and Schools Bill, legislation that will ensure teachers and schools are involved in decisions concerning the safeguarding children in their area, and local authorities the power of intervention if a child's home environment is assessed as unsuitable or unsafe. Work and Pensions Secretary Liz Kendall rejects a parliamentary ombudsman recommendation to pay financial compensation to the estimated 3.6 million women born in the 1950s who were adversely affected by changes to the state pension age back in the 2010s.
=== Cases of poisoning === Despite the element's highly hazardous properties, circumstances in which polonium poisoning can occur are rare. Its extreme scarcity in nature, the short half-lives of all its isotopes, the specialised facilities and equipment needed to obtain any significant quantity, and safety precautions against laboratory accidents all make harmful exposure events unlikely. As such, only a handful of cases of radiation poisoning specifically attributable to polonium exposure have been confirmed.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.